Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 14, 2025

Advancing Early Alzheimer Diagnosis: Best Practices for Timely Screening and Detection

Panelists discuss how health care institutions employ comprehensive screening protocols for Alzheimer disease, including cognitive assessments, biomarker testing, and regular monitoring of at-risk populations, to facilitate early symptom identification and timely diagnosis that enables prompt intervention and improved patient outcomes.

Episodes in this series

EP. 1 Strategies for Enhancing Early Diagnosis and Implementation of Disease-Modifying Therapies in Alzheimer Disease

EP. 1 Strategies for Enhancing Early Diagnosis and Implementation of Disease-Modifying Therapies in Alzheimer Disease

4 experts are featured in this series.

EP. 2 Advancing Early Alzheimer Diagnosis: Best Practices for Timely Screening and Detection

4 experts are featured in this series.

EP. 3 Care Pathways for Nonspecialist Providers When Evaluating Patients With Potential Mild Cognitive Impairment

4 experts are featured in this series.

EP. 4 Empowering Nonspecialist Providers and Addressing Gaps in Dementia Care: How Tools and Biomarkers Can Help

4 experts are featured in this series.

EP. 5 Factors to Evaluate When Selecting a Combination of Screening Assessments and Tests for Detecting Alzheimer Disease

4 experts are featured in this series.

EP. 6 From Time Constraints to Reimbursement: Addressing Key Hurdles in Cognitive Screening for Alzheimer Disease

4 experts are featured in this series.

EP. 7 Expanding Access to Alzheimer Disease Care: Leveraging Referral Networks and Telemedicine for Patients in Underserved Areas

4 experts are featured in this series.

EP. 8 Amyloid-Targeting Therapies in Alzheimer Disease: Mechanisms of Action, Efficacy, and Safety Considerations

4 experts are featured in this series.

EP. 9 Real-World Implications of Changes in CDR-SB Score in Patients Receiving Amyloid-Targeting Therapy

4 experts are featured in this series.

EP. 10 Patient Selection for Amyloid-Targeting Therapies: Key Characteristics and Considerations

4 experts are featured in this series.

EP. 11 Understanding the Hesitancy to Prescribe Amyloid-Targeting Therapies for Patients With Alzheimer Disease

4 experts are featured in this series.

EP. 12 Navigating the Risk-Benefit Conversation: Discussing Amyloid-Targeting Therapies With Patients and Caregivers

4 experts are featured in this series.

EP. 13 Criteria for Discontinuing Treatment With an Amyloid-Targeting Therapy

4 experts are featured in this series.

EP. 14 Strategies for Clinicians When Developing Protocols for Managing ARIA

4 experts are featured in this series.

EP. 15 Key Barriers in Managing Patients With Mild Cognitive Impairment Using Amyloid-Targeting Therapies

4 experts are featured in this series.

EP. 16 Access to Diagnostic Tests and Coverage for Amyloid-Targeting Therapies: Payer Considerations

4 experts are featured in this series.

EP. 17 Addressing Concerns About the Financial Impact of Amyloid-Targeting Therapies

4 experts are featured in this series.

EP. 18 Final Thoughts Alzheimer Disease Care

Video content above is prompted by the following:

What are the current best practices your institution uses to screen for Alzheimer disease to ensure timely identification of symptoms and early diagnosis?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Dr Irina Murakhovskaya | Image Credit: Montefiore Einstein

ENERGY Trial Shows Early Fatigue Benefit With Nipocalimab in wAIHA: Irina Murakhovskaya, MD

ByBrooke McCormick,Irina Murakhovskaya, MD

June 26th 2026

CRC animation | Image Credit: Thipphaphone - stock.adobe.com

Early-Life, Parental Factors May Help Explain Rising Early-Onset CRC Rates

ByBrooke McCormick

June 26th 2026

This segment explores how emerging data on oral selective estrogen receptor degraders are being applied in clinical practice for hormone receptor–positive, HER2-negative metastatic breast cancer.

HR-Positive Breast Cancer: Clinical Use of Oral SERDs in Combination vs Monotherapy

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

This segment introduces the evolving treatment landscape in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on the growing clinical relevance of ESR1 mutations.

HR-Positive Breast Cancer: Evolving Role of ESR1 Mutations in Endocrine Resistance

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

Stamp that says "FDA Approved" in blue ink. | Image Credit: Surendra - stock.adobe.com

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

ByElla Hohmann, MS

June 25th 2026

Trending on AJMC

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor

Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma

Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis